SPRING HOUSE, PENNSYLVANIA, May 31, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment. | May 31, 2023
RARITAN, NJ,May 30, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a New Drug Application to the U.S. Food and Drug Administration . | May 30, 2023
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new efficacy and safety data from the Phase 3 QUASAR Induction Study.
that cause chronic inflammation of the gastrointestinal tract.6 Prolonged inflammation results in damage to the GI tract.6 The exact cause of IBD is unknown but may be the result of the immune. | May 9, 2023
High Wycombe, 21 April 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson is pleased to announce that the National Institute for Health and Care Excellence (NICE) has recommended Imbruvica® (ibrutinib) plus venetoclax as an option for untreated chronic lymphocytic leukaemia (CLL) in adult.